Recent Finacing
Recent Raise
Helix Therapeutics develops a Yale-licensed targeted gene modification platform to correct mutations in blood stem cells for disorders including sickle cell disease, beta-thalassemia, and lysosomal storage disorders.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors